Compare FURY & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FURY | MGNX |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 94.9M |
| IPO Year | N/A | 2013 |
| Metric | FURY | MGNX |
|---|---|---|
| Price | $0.59 | $1.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | $1.40 | ★ $3.20 |
| AVG Volume (30 Days) | 554.5K | ★ 821.9K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $127,626,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $0.99 |
| 52 Week High | $0.89 | $3.77 |
| Indicator | FURY | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 43.54 |
| Support Level | $0.50 | $1.33 |
| Resistance Level | $0.63 | $1.55 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 71.38 | 21.95 |
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.